Please login to the form below
Anaveon
This page shows the latest Anaveon news and features for those working in and with pharma, biotech and healthcare.
Novartis and Syncona back new Swiss biotech Anaveon
Founders focused on IL-2 Receptor Agonists. Novartis' venture fund arm and Syncona are supporting new Switzerland-based immuno-oncology specialists Anaveon. ... re-direction of IL-2 activity in vivo, Anaveon has developed biologic approaches for the
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
- OPEN Health and Nested Knowledge announce strategic research collaboration to leverage AI technologies for evidence synthesis
- FDA approves two cell-based gene therapies for sickle cell disease
- Pfizer’s Elrexfio granted EC approval for relapsed and refractory multiple myeloma
- New economic data reveals risk of disincentivising UK life sciences growth
- WHO countries hold seventh INB meeting to prevent global pandemics
- The start of a beautiful friendship
No results were found
PMHub
11 London
We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our...
Latest intelligence
- Virtual care – negotiating barriers to adoption offers glimpses of an exciting future
- Digital tools and innovative healthcare promise to address pressing healthcare issues if they can satisfy concerns over access, security and affordability...
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
